
Shares of gene therapy maker bluebird bio BLUE.O fall 38.6% to $4.32 premarket
Co says it would be taken private by Carlyle CG.O and SK Capital Partners
BLUE stockholders will receive $3/shr in cash, implying an equity value of around $29.2 mln
The offer is at an over 57% discount from the stock's last close of $7.04
Investment firms have also offered additional $6.84/shr, contingent upon achieving certain sales milestones, which represents a payment of about $66.5 mln
BLUE fell 69.8% in 2024